Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Gregory Rossi"'
Background: Specific data regarding coronavirus disease 2019 (COVID-19) in pa-tients with neuroendocrine neoplasms (NENs) are lacking. The aim of this study is to describe the characteristics of patients with NENs who tested severe acute respiratory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::4331c084de76986822e1c96752acb61c
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3030151
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3030151
Autor:
Peter Paul Yu, Patricia A. Ganz, J. Russell Hoverman, Dana S. Wollins, Julie M. Vose, Thomas J. Smith, Gary H. Lyman, Gregory Rossi, Douglas W. Blayney, Robert M. Langdon, Leonard B. Saltz, Deborah Schrag, Derek Raghavan, Richard L. Schilsky, Lowell E. Schnipper, Therese M. Mulvey, Lee N. Newcomer, Nancy E. Davidson, Blase N. Polite, Jeffrey Peppercorn, Adam P. Dicker, Neal J. Meropol, Clifford A. Hudis
Publikováno v:
Journal of Clinical Oncology. 34:2925-2934
The mission of American Society of Clinical Oncology (ASCO) is to conquer cancer through research, education, and promotion of the highest quality patient care. Toward fulfillment of this goal and at the direction of its board of directors, the ASCOV
Autor:
Peter Paul Yu, Deborah Schrag, Lowell E. Schnipper, Blase N. Polite, Diane Blum, Leonard B. Saltz, Therese M. Mulvey, J. Russell Hoverman, Adam P. Dicker, Lee N. Newcomer, Patricia A. Ganz, Derek Raghavan, Gregory Rossi, Thomas J. Smith, Nancy E. Davidson, Neal J. Meropol, Dana S. Wollins, Richard L. Schilsky, Clifford A. Hudis, Douglas W. Blayney, Courtney Tyne, Gary H. Lyman, Jeffrey Peppercorn, Robert M. Langdon
Publikováno v:
Journal of Clinical Oncology. 33:2563-2577
Health care costs in the United States present a major challenge to the national economic well being. The Centers for Medicare and Medicaid Services (CMS) has projected that US health care spending will reach $4.3 trillion and account for 19.3% of th
Autor:
Joshua T. Cohen, Gregory Rossi, Pei-Jung Lin, Hannah R. Auerbach, Jeffrey Hille, C Fang, Peter J. Neumann, Thomas W Concannon, Eric Nadler, Dan Greenberg
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 13:513-522
To investigate the relationship between the framing of survival gains and the perceived value of cancer care.Through a population-based survey of 2040 US adults, respondents were randomized to one of the two sets of hypothetical scenarios, each of wh
Autor:
Gregory. Rossi
Publikováno v:
The Missouri Review. 29:30-45
Autor:
Saroj, Vadhan-Raj, Barry, Mirtsching, Veena, Charu, Dixon, Terry, Gregory, Rossi, Dianne, Tomita, William P, McGuire
Publikováno v:
The journal of supportive oncology. 1(2)
The objective of this ongoing trial is to study the ability of darbepoetin alfa to reverse chemotherapy-induced anemia in cancer patients, and to relate improvement in hemoglobin with changes in fatigue and functional capacity. Eligible subjects had
Autor:
Michael, Hedenus, Magnus, Adriansson, Jesus, San Miguel, Mark H H, Kramer, Martin R, Schipperus, Eeva, Juvonen, Kerry, Taylor, Andrew, Belch, Albert, Altés, Giovanni, Martinelli, David, Watson, James, Matcham, Gregory, Rossi, Timothy J, Littlewood
Publikováno v:
British journal of haematology. 122(3)
This phase 3, randomized, double-blind, placebo-controlled study was designed to evaluate the efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Patients (n = 344) with lymphoma or myeloma received darb
Publikováno v:
Oncology (Williston Park, N.Y.). 16(10 Suppl 11)
Our objective was to evaluate the effects of darbepoetin alfa (Aranesp) on hemoglobin and transfusions in anemic patients with cancer undergoing chemotherapy, and the impact of age, sex, baseline hemoglobin, chemotherapy type, and tumor type. Patient
Publikováno v:
Oncology (Williston Park, N.Y.). 16(10 Suppl 11)
Our objective was to assess, using clinical trial simulation, the feasibility of a fixed 200-microg dose of darbepoetin alfa (Aranesp) administered every 2 weeks in chemotherapy-induced anemia. A pharmacokinetic/pharmacodynamic model was developed us
Autor:
Barry, Mirtsching, Veena, Charu, Saroj, Vadhan-Raj, Alan B, Colowick, Gregory, Rossi, Dianne, Tomita, William P, McGuire
Publikováno v:
Oncology (Williston Park, N.Y.). 16(10 Suppl 11)
The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 microg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by pooling data from three darbepoe